Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(RS)-AMPA hydrobromide is a more water soluble hydrobromide salt of (RS)-AMPA (Cat. No. 0169).
分子量 | 267.08 |
公式 | C7H10N2O4.HBr |
储存 | Desiccate at +4°C |
纯度 | ≥99% (HPLC) |
CAS Number | 171259-81-7 |
PubChem ID | 11957558 |
InChI Key | KUAHVIUZGLGASU-UHFFFAOYSA-N |
Smiles | Br.CC1=C(CC(N)C(O)=O)C(O)=NO1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
water | 2.67 | 10 温和加热 |
以下数据基于产品分子量 267.08。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 37.44 mL | 187.21 mL | 374.42 mL |
0.5 mM | 7.49 mL | 37.44 mL | 74.88 mL |
1 mM | 3.74 mL | 18.72 mL | 37.44 mL |
5 mM | 0.75 mL | 3.74 mL | 7.49 mL |
参考文献是支持产品生物活性的出版物。
Honore et al (1982) The binding of 3H-AMPA, a structural analogue of glutamic acid, to rat brain membranes. J.Neurochem. 38 173 PMID: 6125564
Krogsgaard-Larsen et al (1980) New class of glutamate agonist structurally related to ibotenic acid. Nature 284 64 PMID: 6101908
Ko et al (2021) Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. Viruses 13 PMID: 33918958
If you know of a relevant reference for (RS)-AMPA hydrobromide, please let us know.
关键词: (RS)-AMPA hydrobromide, (RS)-AMPA hydrobromide supplier, water, soluble, Glutamate, AMPA, Receptors, iGlur, Ionotropic, 1074, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 (RS)-AMPA hydrobromide 的部分引用包括:
Iskandrani et al (2015) Impact of subanesthetic doses of KA on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons. J Neurosci 29 792 PMID: 25759403
Wasling et al (2012) AMPA receptor activation causes silencing of AMPA receptor-mediated synaptic transmission in the developing hippocampus. PLoS One 7 e34474 PMID: 22485173
Pierrot et al (2019) Sex-regulated gene dosage effect of PPARα on synaptic plasticity. Life Sci Alliance 2 PMID: 30894406
Chanda et al (2013) Neurons generated by direct conversion of fibroblasts reproduce synaptic phenotype caused by autism-associated neuroligin-3 mutation. J Psychopharmacol 110 16622 PMID: 24046374
Goo et al (2017) Activity-dependent trafficking of lysosomes in dendrites and dendritic spines. J Cell Biol 216 2499 PMID: 28630145
您是否知道使用了 Tocris (RS)-AMPA hydrobromide 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review (RS)-AMPA hydrobromide and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.